{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:41:58Z","timestamp":1789177318318,"version":"build-2803163510"},"reference-count":133,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.1080\/17425255.2024.2367593","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T16:16:17Z","timestamp":1718468177000},"page":"473-489","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting"],"prefix":"10.1080","volume":"20","author":[{"given":"Adile","family":"Orhan","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Zealand University Hospital Roskilde, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Nguyen","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Chan","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, Irvine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Zealand University Hospital Roskilde, Roskilde, Denmark"},{"name":"Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000450"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08220-5"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1963.03710020036011"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(84)90010-0"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/1801200a0"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/277093a0"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(92)90025-2"},{"issue":"3","key":"e_1_3_4_10_1","first-page":"358","article-title":"Dual mechanism of anti-emetic action of 10(gamma-dimethylaminopropyl)-2-chlorophenothiazine hydrochloride (chlorpromazine) in dogs","volume":"114","author":"Glaviano V","year":"1955","unstructured":"Glaviano V, Wang SC. Dual mechanism of anti-emetic action of 10(gamma-dimethylaminopropyl)-2-chlorophenothiazine hydrochloride (chlorpromazine) in dogs. J Pharmacol Exp Ther. 1955;114(3):358\u2013366.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050222"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm000090i"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197612020-00001"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(79)90236-1"},{"key":"e_1_3_4_15_1","first-page":"4384","article-title":"Le m\u00e9toclopramideetses homologues. Introduction \u00e0 leur\u00e9tudebiologigue","volume":"258","author":"Justin-Besancon L","year":"1964","unstructured":"Justin-Besancon L, Laville C, Thominet M. Le m\u00e9toclopramideetses homologues. Introduction \u00e0 leur\u00e9tudebiologigue. CR AcadSci (Paris). 1964;258:4384\u20134386.","journal-title":"CR AcadSci (Paris)"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb01028.x"},{"key":"e_1_3_4_17_1","unstructured":"U.S. Food and Drug Administration. Metoclopramide orally disintegrating tablets. n.d. [cited 2023 Oct 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021793lbl.pdf"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1586\/eem.10.41"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm15130"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198110153051601"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1986.tb10228.x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(19)33898-3"},{"key":"e_1_3_4_23_1","first-page":"344","article-title":"Metoclopramide versus prochlorperazine in the prevention of vomiting from cisdiamminedichloroplatinum","volume":"21","author":"Arnold DJ","year":"1980","unstructured":"Arnold DJ, Ribiero V, Bulkin W. Metoclopramide versus prochlorperazine in the prevention of vomiting from cisdiamminedichloroplatinum. Proc Am Soc Clin Oncol. 1980;21:344.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_3_4_24_1","first-page":"421","article-title":"A double-blind comparison of metoclopramide and prochlorperazine as antiemetics for platinum therapy","volume":"22","author":"Frytak S","year":"1981","unstructured":"Frytak S, Moertel CG, Eagan RT, et al. A double-blind comparison of metoclopramide and prochlorperazine as antiemetics for platinum therapy. Proc Am Soc Clin Oncol. 1981;22:421.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_3_4_25_1","first-page":"1106","article-title":"A single dose of metoclopramide in the control of vomiting from cis-dichlorodiammineplatinum(II) in man","volume":"7","author":"Kahn T","year":"1978","unstructured":"Kahn T, Elias EG, Mason GR. A single dose of metoclopramide in the control of vomiting from cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1978;7:1106\u20131107.","journal-title":"Cancer Treat Rep"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050155"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.1.108"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv132"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.11.864"},{"key":"e_1_3_4_31_1","unstructured":"Isola S Hussain A Dua A et al. Metoclopramide. StatPearls [Internet]. 2023 Sep 4 [cited 2023 Oct 18]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519517\/"},{"key":"e_1_3_4_32_1","unstructured":"European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. 2013 Dec 20 [cited 2024 Jun 20].Available from: https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-changes-use-metoclopramide"},{"key":"e_1_3_4_33_1","first-page":"83","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity","volume":"280","author":"Schoemaker H","year":"1997","unstructured":"Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity. J Pharmacol Exp Ther. 1997;280:83\u201397.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199907000-00002"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02869-1"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00909-8"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.320"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S234256"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1714029"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S117321"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3825-2"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4564-8"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S6226"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0065-1591.2000.007s021[dash]5.x"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03770.x"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.2165\/00024669-200605020-00006"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686023"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2006.12.004"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1690"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304153281502"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.2091"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690372"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050291"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0158-y"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01681960"},{"key":"e_1_3_4_56_1","volume-title":"Prochlorperazine","author":"Din L","year":"2024","unstructured":"Din L, Preuss CV. Prochlorperazine. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan."},{"key":"e_1_3_4_57_1","unstructured":"Prochlorperazine. AA Pharma Inc. 2012 Aug 31 [cited2023 Oct 19]. Available from: https:\/\/www.aapharma.ca\/downloads\/en\/PIL\/Prochlorazine_PI.pdf"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1991.tb03973.x"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03021.x"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005281044"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.07.027"},{"issue":"5","key":"e_1_3_4_62_1","first-page":"637","article-title":"Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects","volume":"70","author":"Ison PJ","year":"1986","unstructured":"Ison PJ, Peroutka SJ. Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects. Cancer Treat Rep. 1986;70(5):637\u2013641.","journal-title":"Cancer Treat Rep"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2019.05.006"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90006-N"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70325-9"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000145983.35929.2a"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2011.0058"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2009"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2022.2057297"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049909111423094"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937060-00001"},{"issue":"1","key":"e_1_3_4_72_1","first-page":"20","article-title":"Elimination half-life and bioavailability of haloperidol in schizophrenic patients","volume":"46","author":"Magliozzi JR","year":"1985","unstructured":"Magliozzi JR, Hollister LE. Elimination half-life and bioavailability of haloperidol in schizophrenic patients. J Clin Psychiatry. 1985;46(1):20\u201321.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.7b00018"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.9.1397"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.7.782"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.18.00245"},{"key":"e_1_3_4_77_1","unstructured":"NCCN Guidelines Version 1. Antiemesis. 2024 [cited 2024 Jan 3]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4177263"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2003.39.7.799445"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225020-00004"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.03.003"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0087-7"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4377-3548-2.00195-6"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13093"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666160-00009"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/61.3.297"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200204000-00029"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197907053010116"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.59.694.500"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.01.027"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03018945"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060505"},{"key":"e_1_3_4_93_1","unstructured":"Food and Drug Administration. FDA Talk Paper: FDA Strengthens Warnings for Droperidol. Pub. No. T01-62. [2001 Dec 5]."},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2013.03.026"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006938.pub3"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01255.x"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02156.x"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189515"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03334.x"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189516"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90528-S"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17466"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00257152"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.295.6592.250"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(87)90255-0"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-023-00413-x"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000001673"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14737"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16162985"},{"key":"e_1_3_4_110_1","unstructured":"European Medicines Agency. CMDH confirms recommendations on restricting use of domperidone-containing medicines. 2014 Apr 25 [cited 2024 Jun 20]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/cmdh-confirms-recommendations-restricting-use-domperidone-containing-medicines#:~:text=The%20CMDh%20confirmed%20by%20majority by%20mouth%20for%20adults%20and"},{"issue":"9","key":"e_1_3_4_111_1","first-page":"442","article-title":"Olanzapine","volume":"58","author":"Hale AS","year":"1997","unstructured":"Hale AS. Olanzapine. Br J Hosp Med. 1997;58(9):442\u2013445.","journal-title":"Br J Hosp Med"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05935-7"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4593-3"},{"key":"e_1_3_4_114_1","volume-title":"Olanzapine","author":"Thomas K","year":"2023","unstructured":"Thomas K, Saadabadi A. Olanzapine. In: StatPearls. Treasure Island (FL). Statpearls Publishing; 2023."},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245608"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115626349"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01399-1"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29110650"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101771"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1710-6"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08224-1"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.11.1686"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1108\/mi.2015.5871"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-131"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.05.003"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012555"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05380-6"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2022.23.6.2137"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.12.006"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00628-9"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.09.072"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2367593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T14:31:53Z","timestamp":1719325913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2367593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,2]]},"references-count":133,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,2]]}},"alternative-id":["10.1080\/17425255.2024.2367593"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2367593","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}